Founding Partner of Securities Law Firm Anthony L.G., Laura Anthony, Appointed to Aditx Therapeutics’ Board of Directors an...
July 24 2020 - 8:00AM
via NEWMEDIAWIRE -- Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
technologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming, today
announced that it has appointed Laura Anthony to the Company’s
Board of Directors, effective as of July 2, 2020.
Ms. Anthony will be an independent director in
accordance with the applicable rules of the Nasdaq Stock Market
LLC. She will serve as the Chair of the Corporate Governance
Committee and will serve on the Audit and Compensation Committee as
well.
Amro Albanna, Co-founder and Chief Executive
Officer of Aditxt, commented, “On behalf of the Board, we’re
pleased to welcome Laura to Aditxt’s Board of Directors. We believe
that the high regard of her legal expertise, including extensive
experience as corporate counsel to both private and public
companies, will benefit Aditxt as we work to execute and advance
our strategic plans. We look forward to working with Laura and her
contribution to our growth and development.”
Ms. Anthony is the founding partner of Anthony
L.G., PLLC, a corporate, securities and business transactions law
firm and has been practicing law since 1993. Ms. Anthony provides
corporate counsel to small-cap and middle market private and public
companies. For over twenty-five years, Ms. Anthony has served
clients in the areas of compliance with the Securities Act of 1933,
including private and public offerings; NASDAQ and NYSE initial and
continued listing requirements; registration and reporting
requirements under the Securities Exchange Act of 1934; initial
public offerings, follow-on offerings and mergers and acquisitions;
and general contract and business transactions. Ms. Anthony
received a juris doctorate from Florida State University College of
Law in 1993.
About Aditx Therapeutics
Aditxt is developing technologies specifically
focused on improving the health of the immune system through immune
monitoring and reprogramming. The immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. The immune reprogramming technology is currently at
the pre-clinical stage and is designed to retrain the immune system
to induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of the federal
securities laws. Words such as “may,” “might,” “will,” “should,”
“believe,” “expect,” “anticipate,” “estimate,” “forecast,”
“project,” “plan,” “intend” or similar expressions, or statements
regarding intent, belief, or current expectations, including the
Company’s expectations regarding the proposed offering of the
Company’s shares of common stock, including as to the consummation
of the offering described above and the size of the offering are
forward-looking statements. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward looking statements are based upon current estimates
and assumptions and are subject to various risks and uncertainties,
including without limitation those set forth in the Company’s
filings with the Securities and Exchange Commission, including, but
not limited to, risk factors relating to its business contained
therein. Thus, actual results could be materially different. The
Company expressly disclaims any obligation to update or alter
statements whether as a result of new information, future events or
otherwise, except as required by law.
Contacts
Investor Relations:
PCG Advisory: Jeff RamsonChief Executive
OfficerIR@aditxt.com 646-762-4518www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jul 2023 to Jul 2024